Stelara

Product manufactured by Janssen Biotech, Inc.

Application Nr Approved Date Route Status External Links
BLA761044 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Stelara ® Is A Human Interleukin-12 And -23 Antagonist Indicated For The Treatment Of: Adult Patients With: Moderate To Severe Plaque Psoriasis (Ps) Who Are Candidates For Phototherapy Or Systemic Therapy. ( 1.1 ) Active Psoriatic Arthritis (Psa) , Alone Or In Combination With Methotrexate. ( 1.2 ) Moderately To Severely Active Crohn's Disease (Cd) . ( 1.3 ) Moderately To Severely Active Ulcerative Colitis. ( 1.4 ) Pediatric Patients 6 Years And Older With: Moderate To Severe Plaque Psoriasis , Who Are Candidates For Phototherapy Or Systemic Therapy. ( 1.1 ) 1.1 Psoriasis (Ps) Stelara ® Is Indicated For The Treatment Of Patients 6 Years Or Older With Moderate To Severe Plaque Psoriasis Who Are Candidates For Phototherapy Or Systemic Therapy. 1.2 Psoriatic Arthritis (Psa) Stelara ® Is Indicated For The Treatment Of Adult Patients With Active Psoriatic Arthritis. Stelara ® Can Be Used Alone Or In Combination With Methotrexate (Mtx). 1.3 Crohn's Disease (Cd) Stelara ® Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Crohn's Disease. 1.4 Ulcerative Colitis Stelara ® Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ustekinumab

Comments